Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection

Trial Profile

ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SER 109 (Primary)
  • Indications Clostridium difficile infections
  • Focus Therapeutic Use
  • Acronyms ECOSPOR
  • Sponsors Seres Therapeutics
  • Most Recent Events

    • 08 Oct 2017 Results of this trial and another one (refer CTP: 700247159) assessing gut microbiome changes were presented at the IDWeek 2017
    • 04 May 2017 According to Seres Therapeutics media release, data from this study was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting.
    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top